Globe on Blue Background with abstract mountains

Registration is now open for the IASLC 2021 World Conference on Lung Cancer

Early Registration is open through July 30, 2021.
Abstract submissions will be accepted through April 9, 2021.
Blue image with Lungs

Thank you for attending the IASLC 2021 CT Screening Symposium: Forefront Advances in Lung Cancer Screening

Content and Registration is available until July 31, 2021
Annual Report 2020

2020 Annual Report


Registration is now open for the IASLC 2021 World Conference on Lung Cancer
Thank you for attending the IASLC 2021 CT Screening Symposium: Forefront Advances in Lung Cancer Screening
2020 Annual Report

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

In Focus

Understanding Treatment Options and Resistance in EGFR-positive NSCLC

Unfortunately, the inevitability of therapeutic resistance is always looming for patients with EGFR-mutated lung cancer, regardless of PD-1/PD-L1 status. Dr. Karen Reckamp—together with Drs. Ibiaya Dagogo-Jack, Ticiana Leal, and Daniel Tan, as well as patient advocate Sarah Christ—talks through a patient case, exploring all facets of the care continuum for this population. Beginning with discussion of biomarker testing and next-generation sequencing and moving through various opinions on use of whole-brain radiation therapy, combination chemotherapy, first-/second-generation TKIs, and/or osimertinib (depending on region) to other still unidentified mechanisms of resistance to EGFR TKI treatment and ongoing trials looking at novel therapeutic strategies. The ultimate goals of prolonging progression-free survival in the frontline setting and having patients living longer and better lives are reinforced in this forum. Although the patient on the case went on to the ORCHARD trial, each expert weighs in with their individual considerations for potential care paths, based on region and on emerging data.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
13.357
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

IASLC Meeting
Oct 29 - Oct 30 2021
IASLC Meeting
Dec 03 - Dec 04 2021
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

JTO

Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating TKI-failed Leptomeningeal Metastases from EGFR-mutant NSCLC—A Prospective Open-label Single-arm Phase I/II Clinical Trial (unique identifier: ChiCTR1800016615)

Chengjuan Fan
+more
May 09, 2021